Bragar Eagel & Squire Urges Picard Medical Investors to Contact Firm Before April 3 Deadline

Law firm announces class action lawsuit against Picard Medical over alleged fraudulent stock promotion scheme

Mar. 31, 2026 at 8:49pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of stock trading documents, a broken calculator, and a shattered smartphone screen, all arranged elegantly on a clean, monochromatic seamless background. The objects conceptually represent the abstract corporate strategy, finance, risk, and markets impacted by the alleged fraudulent activity.A shattered financial landscape exposes the fallout from alleged stock manipulation and misleading disclosures.San Jose Today

Bragar Eagel & Squire, P.C., a national stockholder rights law firm, has filed a class action lawsuit against Picard Medical, Inc. (NYSE:PMI) in the U.S. District Court for the Northern District of California on behalf of investors who purchased Picard securities between September 2, 2025 and October 31, 2025. The lawsuit alleges that Picard failed to disclose that the company was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals, as well as insider trading through offshore or nominee accounts.

Why it matters

The lawsuit against Picard Medical highlights the growing issue of stock manipulation through social media and other online channels, which can lead to significant losses for unsuspecting investors. This case raises questions about the effectiveness of financial regulations and the need for greater transparency and oversight in the stock market.

The details

According to the complaint, Picard's stock price abruptly crashed 70% on October 24, 2025, falling from over $13 per share to $3.99 per share. Since then, the company's share price has continued to decline to around $2.00 per share. The lawsuit alleges that Picard failed to disclose to investors that the company was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals, as well as insider trading through offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign.

  • Investors have until April 3, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • The class period covers purchases or acquisitions of Picard securities between September 2, 2025 and October 31, 2025.

The players

Bragar Eagel & Squire, P.C.

A nationally recognized stockholder rights law firm that filed the class action lawsuit against Picard Medical on behalf of investors.

Picard Medical, Inc.

A publicly traded medical device company that is the subject of the class action lawsuit over alleged fraudulent stock promotion and insider trading.

Got photos? Submit your photos here. ›

What they’re saying

“If you purchased or acquired Picard securities between September 2, 2025, and October 31, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.”

— Brandon Walker or Melissa Fortunato, Bragar Eagel & Squire Partners

What’s next

Investors have until April 3, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit against Picard Medical.

The takeaway

This case highlights the growing problem of stock manipulation through social media and other online channels, which can lead to significant losses for investors. It raises questions about the need for greater transparency and oversight in the stock market to protect individual investors from fraudulent schemes.